Natco Pharma Bolsters US Oncology Portfolio with Pomalidomide Launch

ma Limited (NSE: NATCOPHARM) has reached a major milestone in its expansion strategy, announcing the official launch of Pomalidomide Capsules in the U.S. market. The launch, conducted in partnership with Breckenridge Pharmaceutical, Inc., introduces a generic version of the high-value brand Pomalyst® (originally developed by Celgene). Tapping into a $3.2 Billion Market The launch is strategically timed to capitalize on a massive market opportunity. According to industry sales data, Pomalidomide Capsules recorded estimated annual sales of approximately $3.2 billion in the U.S. for the 12-month period ending September 2025. Key highlights of the launch include: Strengths Available: 1 mg, 2 mg, 3 mg, and 4 mg capsules. Market Exclusivity: Based on FDA information, Natco believes it is entitled to 180 days of shared exclusivity, providing a critical competitive window during the initial rollout. Distribution: The product will be distributed primarily through specialty pharmacies and clinics to ensure targeted patient access.